EuroPCR 24 - In this succinct interview, we are joined by Dr Hans-Josef Feistritzer (University of Leipzig, DE) to discuss the findings of the SOLVE-TAVI Trial.

In recent years, trials such as CHOICE, REPRISE III, the SCOPE trial, PORTICO IDE and the SMART trial have privided increasing evidence for direct TACI valve comparisons as device designs improve. TAVI is increasingly performed using local anaesthesia and conscious sedation, or local anaesthesia only.

The SOLVE-TAVI trial used a 2x2 factorial design to compare both valve strategies (CoreValve Evolut R or Edwards Sapien 3) and anaesthesia strategies (conscious sedation and general anaesthesia) in a group of 447 patients with symptomatic aortic stenosis and an indication for TAVR.

Findings showed similar outcomes in both valve groups at 5 years, though stroke rate was higher in the Sapien 3 group. In terms of anaesthesia strategy, conscious sedation and general anaesthesia both resulted in similar outcomes in regard to the composite primary endpoint at 5 years, though mortality was lower in the conscious sedation group.

Interview Questions:

1. What is the importance of SOLVE-TAVI?
2. What was the study design, eligibility criteria and outcome measures?
3. What are the findings presented at EuroPCR 24?
4. What are the take-home messages for practice?
5. What are the next steps?

Recorded onsite at EuroPCR 2024, Paris